Recombinant LAG3 (Relatlimab Biosimilar) antibody

Catalog No. ABIN7795123

This anti-LAG3 (Relatlimab Biosimilar) antibody is a Mouse Monoclonal antibody detecting LAG3 (Relatlimab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant LAG3 (Relatlimab Biosimilar) antibody (ABIN7795123)

Target: LAG3 (Relatlimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This LAG3 (Relatlimab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-LAG3 (Relatlimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Characteristics: What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human LAG-3

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for LAG3 (Relatlimab Biosimilar)

Target: LAG3 (Relatlimab Biosimilar)

Alternative Name: Relatlimab Biosimilar

Target Type: Biosimilar